Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients

African Health Sciences

Volumn 13, Issue 3, 2013, Pages 703-709

  Li, B ^a   Liu, H ^a   Shang, H W ^b   Li, P ^a   Li, N ^a   Ding, H G ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Alpha fetoprotein; Differential diagnosis; Glypican 3; Hepatitis B; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CARCINOMATOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER LEVEL; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; PARACARCINOMATOUS LIVER; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ALPHA FETOPROTEIN; DIFFERENTIAL DIAGNOSIS; GLYPICAN-3; HEPATITIS B; HEPATOCELLULAR CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; CHINA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYPICANS; HEPATITIS B; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84883664221     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: 10.4314/ahs.v13i3.26     Document Type: Article

References (32)

1. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10: 1111-8.
2. Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, et al. Short-and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008;15: 1670-6.
3. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122. 1609-1619.
4. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a costutility analysis. Br J Cancer 2008;98: 1166-75.
5. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30: 1405-11.
6. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006;14: 266-272.
7. Kakar S, Gown AM, Goodman ZD, Ferrell LD. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007;131: 1648-1654.
8. Stroescu C, Herlea V, Dragnea A, Popescu I. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointestin Liver Dis. 2006;15:9-14.
9. Saad RS, Luckasevic TM, Noga CM, Johnson DR, Silverman JF, Liu YL. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol 2004;30:1-6.
10. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006;14:266-72.
11. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001; 108:497-501.
12. Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, et al. MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 2012;586:884-91.
13. Farooq M, Hwang SY, Park MK, Kim JC, Kim MK, Sung YK. Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest. Mol Cells. 2003;15:356-360.
14. Li L, Jin R, Zhang X, Lv F, Liu L, Liu D, et al. Oncogenic activation of GPC3 by c-Myc in human hepatocellular carcinoma. Hepatology 2012 18. doi: 10.1002/hep.25891.
15. Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y, et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 2012;39(1):351-7.
16. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
17. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-1598.
18. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
19. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16-25.
20. Hirohashi S, Blum HE, Ishak KJ. Hepatocellular Carcinoma. In Who: Pathology & Genetics, Tumour of the digestive system. IARC Press 2000;159-172.
21. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol. 2010;25:657-63.
22. Committee of Liver Cancer, Chinese Anticancer Association. The clinical diagnosis and staging criteria of primary liver cancers. Journal of Chinese Hepatology. 2001; 9: 324-328.
23. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, rt al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568-74
24. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009; 4:e8467.
25. Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, et al. Glypican-3 Immunocytochemistry in Liver Fine-needle Aspirates-A Novel Stain to Assist in the Differentiation of Benign and Malignant Liver Lesions. Cancer (Cancer Cytopathology) 2007; 111: 316-322.
26. Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem 2012;114:547-52.
27. Wang Y, Shen Z, Zhu Z, Han R, Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon 2011;11:195-9.
28. Tremosini S, Forner A, Boix L, Vilana R, Bianchi L, Reig M, et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012doi:10.1136/ gutjnl-2011-301862
29. Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol, 2011;2011:519783.
30. Baumhoer D., Tornillo L., Stadlmann S., Roncalli M., Diamantis EK., Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129:899-906.
31. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793-9.
32. Ozkan H, Erdal H, Koçak E, Tutkak H, Karaeren Z, Yakut M, et al. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal. 2011;25:350-3.